Amanda Proudfoot
18Patents
2h-index
22Co-inventors
54Inventor score
Filing activity: May 23, 1997 → Sep 29, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6159711A | DNA encoding rantes peptide fragments and methods of treatment with the fragments | Human Necessities | 10 | Expired |
| US7740833B2 | Therapeutic uses of chemokine variants | Physics | 4 | Active |
| US7541435B2 | Antagonists of cxcr3-binding cxc chemokines | Human Necessities | 2 | Expired |
| US6555105B1 | Method of treatment with a RANTES antagonist polypeptide | Human Necessities | 1 | Expired |
| US7553483B2 | Chemokine mutants acting as chemokine antagonists | Human Necessities | 1 | Expired |
| US7393660B2 | CC-chemokine binding tick proteins | Human Necessities | 1 | Expired |
| US10017568B2 | Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same | Chemistry; Metallurgy | 1 | Active |
| US7635576B2 | CC-chemokine binding tick proteins | Emerging Cross-Sectional Technologies | 0 | Expired |
| US7476381B2 | Methods of reducing serum alanine transferase levels in a subject with hepatitis | Human Necessities | 0 | Expired |
| US7335350B2 | Chemokines mutants having improved oral bioavailability | Human Necessities | 0 | Expired |
| US7803910B2 | Soluble CD164 polypeptides | Human Necessities | 0 | Expired |
| US7670802B2 | CXC-chemokine antagonists isolated from Rhipicephalus sanguineus | Human Necessities | 0 | Active |
| US6902728B1 | Chemokine receptor antagonist and cyclosporin in combined therapy | Human Necessities | 0 | Expired |
| US7611867B2 | CC-chemokine binding tick proteins | Chemistry; Metallurgy | 0 | Active |
| US10829552B2 | Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same | Chemistry; Metallurgy | 0 | Active |
| US11773159B2 | Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same | Chemistry; Metallurgy | 0 | Active |
| US7425324B2 | Antagonists of MCP proteins | Human Necessities | 0 | Expired |
| US7402303B2 | Chemokine mutants in the treatment of multiple sclerosis | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.